Correction: Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery (PLoS ONE (2018) 12:10 (e0185926) DOI: 10.1371/journal.pone.0185926);Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery

PLoS ONE

Volumn 12, Issue 10, 2017, Pages

  Mosconi, Lisa ^a,b   Berti, Valentina ^c   Guyara Quinn, Crystal ^b   McHugh, Pauline ^b   Petrongolo, Gabriella ^b   Osorio, Ricardo S ^b   Connaughty, Christopher ^b   Pupi, Alberto ^c   Vallabhajosula, Shankar ^a   Isaacson, Richard S ^a   De Leon, Mony J ^b   Swerdlow, Russell H ^d   Brinton, Roberta Diaz ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; BIOENERGY; CLIMACTERIUM; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENDOPHENOTYPE; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MITOCHONDRION; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; AGING; BRAIN; BRAIN MAPPING; DIAGNOSTIC IMAGING; ENERGY METABOLISM; ENZYMOLOGY; MEMORY; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PSYCHOLOGY; THROMBOCYTE;

ADULT; AGING; ALZHEIMER DISEASE; BLOOD PLATELETS; BRAIN; BRAIN MAPPING; ELECTRON TRANSPORT COMPLEX IV; ENERGY METABOLISM; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MEMORY; MIDDLE AGED; MITOCHONDRIA; NEUROPSYCHOLOGICAL TESTS; PERIMENOPAUSE; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; POSTMENOPAUSE; RADIOPHARMACEUTICALS;

EID: 85031009384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0193314     Document Type: Erratum

References (60)

1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997; 278(16):1349–56. PMID: 9343467.
2. Alzheimer’s A. 2016 Alzheimer’s disease facts and figures. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2016; 12(4):459–509. PMID: 27570871.
3. Vina J, Lloret A. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. Journal of Alzheimer’s disease: JAD. 2010; 20 Suppl 2:S527–33. https://doi.org/10.3233/JAD-2010-100501 PMID: 20442496.
4. Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nature reviews Endocrinology. 2015; 11(7):393–405. https://doi.org/10.1038/nrendo.2015.82 PMID: 26007613.
5. Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nature reviews Neurology. 2013; 9(1):54–8. https://doi.org/10.1038/nrneurol.2012.241 PMID: 23183885; PubMed Central PMCID: PMC3643203.
6. Brinton RD. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in pharmacological sciences. 2009; 30(4):212–22. https://doi.org/10.1016/j.tips.2008.12.006 PMID: 19299024; PubMed Central PMCID: PMC3167490.
7. Liu F, Day M, Muniz LC, Bitran D, Arias R, Revilla-Sanchez R, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nature neuroscience. 2008; 11 (3):334–43. https://doi.org/10.1038/nn2057 PMID: 18297067.
8. Yao J, Chen S, Mao Z, Cadenas E, Brinton RD. 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer’s disease. PloS one. 2011; 6(7):e21788. https://doi.org/10.1371/journal.pone.0021788 PMID: 21747957; PubMed Central PMCID: PMC3128612.
9. Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012; 75(5):762–77. https://doi.org/10.1016/j.neuron.2012.08.019 PMID: 22958818.
10. Yao J, Brinton RD. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer’s disease. Advances in pharmacology. 2012; 64:327–71. https://doi.org/10.1016/B978-0-12394816-8.00010-6 PMID: 22840752; PubMed Central PMCID: PMC3970844.
11. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006; 443(7113):787–95. https://doi.org/10.1038/nature05292 PMID: 17051205.
12. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. European journal of nuclear medicine and molecular imaging. 2009; 36(5):811–22. https://doi.org/10.1007/s00259-008-1039-z PMID: 19142633; PubMed Central PMCID: PMC2774795.
13. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of aging. 2008; 29(5):676–92. https://doi.org/10.1016/j.neurobiolaging.2006.12.008 PMID: 17222480; PubMed Central PMCID: PMC2430185.
14. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(19):10966–71. https://doi.org/10.1073/pnas.191044198 PMID: 11526211; PubMed Central PMCID: PMC58582.
15. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, et al. Maternal family history of Alzheimer’s disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(48):19067–72. https://doi.org/10.1073/pnas.0705036104 PMID: 18003925; PubMed Central PMCID: PMC2141909.
16. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98(6):3334–9. https://doi.org/10.1073/pnas.061509598 PMID: 11248079; PubMed Central PMCID: PMC30654.
17. Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysi-ological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013; 12(2):207–16. https://doi.org/10.1016/S1474-4422(12)70291-0 PMID: 23332364; PubMed Central PMCID: PMC3622225.
18. Berti V, Mosconi L, Pupi A. Brain: normal variations and benign findings in fluorodeoxyglucose-PET/ computed tomography imaging. PET clinics. 2014; 9(2):129–40. https://doi.org/10.1016/j.cpet.2013.10.006 PMID: 24772054; PubMed Central PMCID: PMC3998066.
19. Wong-Riley MT. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends in neurosciences. 1989; 12(3):94–101. PMID: 2469224.
20. Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. Journal of Alzheimer’s disease: JAD. 2010; 20 Suppl 2:S265–79. https://doi.org/10.3233/JAD-2010-100339 PMID: 20442494; PubMed Central PMCID: PMC2883665.
21. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(34):14670–5. https://doi.org/10.1073/pnas.0903563106 PMID: 19667196; PubMed Central PMCID: PMC2732886.
22. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer’s. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(13):5949–54. https://doi.org/10.1073/pnas.0914141107 PMID: 20231448; PubMed Central PMCID: PMC2851906.
23. De Santi S, Pirraglia E, Barr W, Babb J, Williams S, Rogers K, et al. Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline. Neuropsychology. 2008; 22 (4):469–84. https://doi.org/10.1037/0894-4105.22.4.469 PMID: 18590359; PubMed Central PMCID: PMC2661242.
24. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4):387–95. https://doi.org/10.1097/gme.0b013e31824d8f40 PMID: 22343510; PubMed Central PMCID: PMC3340903.
25. Mosconi L, de Leon M, Murray J, E L, Lu J, Javier E, et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer’s disease. Journal of Alzheimer’s disease: JAD. 2011; 27(3):483–90. https://doi.org/10.3233/JAD-2011-110866 PMID: 21841246; PubMed Central PMCID: PMC3291954.
26. Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer’s disease platelets. Neurobiology of aging. 2004; 25(1):105–10. PMID: 14675736.
27. Parker WD Jr., Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology. 1990; 40(8):1302–3. PMID: 2166249.
28. Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology. 2009; 72(6):513–20. https://doi.org/10.1212/01.wnl.0000333247.51383.43 PMID: 19005175; PubMed Central PMCID: PMC2677512.
29. Joshi A, Koeppe RA, Fessler JA. Reducing between scanner differences in multi-center PET studies. NeuroImage. 2009; 46(1):154–9. https://doi.org/10.1016/j.neuroimage.2009.01.057 PMID: 19457369; PubMed Central PMCID: PMC4308413.
30. Ashburner J, Friston KJ. Voxel-based morphometry—the methods. NeuroImage. 2000; 11(6 Pt 1):805–21. https://doi.org/10.1006/nimg.2000.0582 PMID: 10860804.
31. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2008; 49(3):390–8. https://doi.org/10.2967/jnumed.107.045385 PMID: 18287270; PubMed Central PMCID: PMC3703818.
32. Mosconi L, Murray J, Tsui WH, Li Y, Spector N, Goldowsky A, et al. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology. 2014; 82(9):752–60. https://doi.org/10.1212/WNL.0000000000000181 PMID: 24523481; PubMed Central PMCID: PMC3945651.
33. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. European journal of nuclear medicine and molecular imaging. 2005; 32 (4):486–510. https://doi.org/10.1007/s00259-005-1762-7 PMID: 15747152.
34. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer’s susceptibility gene. Journal of Alzheimer’s disease: JAD. 2010; 22(1):307–13. https://doi.org/10.3233/JAD-2010-100129 PMID: 20847408; PubMed Central PMCID: PMC3124564.
35. Selkoe DJ. Clearing the brain’s amyloid cobwebs. Neuron. 2001; 32(2):177–80. PMID: 11683988.
36. Benzinger TL, Blazey T, Jack CR Jr., Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(47):E4502–9. https://doi.org/10.1073/pnas.1317918110 PMID: 24194552; PubMed Central PMCID: PMC3839740.
37. Mosconi L, McHugh PF. FDG- and amyloid-PET in Alzheimer’s disease: is the whole greater than the sum of the parts? The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine. 2011; 55(3):250–64. PMID: 21532539; PubMed Central PMCID: PMC3290913.
38. Yin F, Yao J, Sancheti H, Feng T, Melcangi RC, Morgan TE, et al. The perimenopausal aging transition in the female rat brain: decline in bioenergetic systems and synaptic plasticity. Neurobiology of aging. 2015; 36(7):2282–95. https://doi.org/10.1016/j.neurobiolaging.2015.03.013 PMID: 25921624; PubMed Central PMCID: PMC4416218.
39. Yao J, Irwin R, Chen S, Hamilton R, Cadenas E, Brinton RD. Ovarian hormone loss induces bioenergetic deficits and mitochondrial beta-amyloid. Neurobiology of aging. 2012; 33(8):1507–21. https://doi.org/10.1016/j.neurobiolaging.2011.03.001 PMID: 21514693; PubMed Central PMCID: PMC3181273.
40. Ding F, Yao J, Rettberg JR, Chen S, Brinton RD. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer’s mouse brain: implication for bioenergetic intervention. PloS one. 2013; 8(11):e79977. https://doi.org/10.1371/journal.pone.0079977 PMID: 24244584; PubMed Central PMCID: PMC3823655.
41. Rettberg JR, Dang H, Hodis HN, Henderson VW, St John JA, Mack WJ, et al. Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer’s risk metabolic phenotype. Neurobiology of aging. 2016; 40:155–63. https://doi.org/10.1016/j.neurobiolaging.2016.01.011 PMID: 26973115; PubMed Central PMCID: PMC4921204.
42. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nature reviews Neuroscience. 2006; 7 (4):278–94. https://doi.org/10.1038/nrn1886 PMID: 16552414; PubMed Central PMCID: PMC3710114.
43. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. The Journal of biological chemistry. 1994; 269(18):13623–8. PMID: 8175797.
44. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP Jr., et al. Cybrids in Alzheimer’s disease: a cellular model of the disease? Neurology. 1997; 49(4):918–25. PMID: 9339668.
45. Miller WL. Steroid hormone synthesis in mitochondria. Molecular and cellular endocrinology. 2013; 379 (1–2):62–73. https://doi.org/10.1016/j.mce.2013.04.014 PMID: 23628605.
46. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstetrics and gynecology. 1994; 83(6):979–83. PMID: 8190445.
47. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, et al. Brain cytochrome oxidase in Alzheimer’s disease. Journal of neurochemistry. 1992; 59(2):776–9. PMID: 1321237.
48. Kanazawa M, Ohba H, Nishiyama S, Kakiuchi T, Tsukada H. Effect of MPTP on Serotonergic Neuronal Systems and Mitochondrial Complex I Activity in the Living Brain: A PET Study on Conscious Rhesus Monkeys. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017; 58 (7):1111–6. https://doi.org/10.2967/jnumed.116.189159 PMID: 28280215.
49. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010; 68 (2):270–81. https://doi.org/10.1016/j.neuron.2010.10.013 PMID: 20955934.
50. Ungar L, Altmann A, Greicius MD. Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction. Brain imaging and behavior. 2014; 8(2):262–73. https://doi.org/10.1007/s11682-013-9272-x PMID: 24293121; PubMed Central PMCID: PMC4282773.
51. Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstetrics and gynecology clinics of North America. 2011; 38(3):519–35. https://doi.org/10.1016/j.ogc.2011.05.007 PMID: 21961718; PubMed Central PMCID: PMC3185244.
52. Rentz DM, Weiss BK, Jacobs EG, Cherkerzian S, Klibanski A, Remington A, et al. Sex differences in episodic memory in early midlife: impact of reproductive aging. Menopause. 2016. https://doi.org/10.1097/GME.0000000000000771 PMID: 27824681.
53. Santoro N. The Study of Women’s Health Across the Nation (SWAN). Obstetrics and gynecology clinics of North America. 2011; 38(3):xvii–xix. https://doi.org/10.1016/j.ogc.2011.07.002 PMID: 21961725.
54. Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014; 82(3):222–9. https://doi.org/10.1212/WNL.0000000000000033 PMID: 24336141; PubMed Central PMCID: PMC3902759.
55. Rasgon NL, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman DH. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PloS one. 2014; 9(3):e89095. https://doi.org/10.1371/journal.pone.0089095 PMID: 24622517; PubMed Central PMCID: PMC3951184.
56. Maki PM, Resnick SM. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiology of aging. 2000; 21(2):373–83. PMID: 10867223.
57. Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause. 2015; 22(4):391–401. https://doi.org/10.1097/GME.0000000000000343 PMID: 25380275; PubMed Central PMCID: PMC4376597.
58. Espeland MA, Brinton RD, Manson JE, Yaffe K, Hugenschmidt C, Vaughan L, et al. Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. Neurology. 2015; 85(13):1131–8. https://doi.org/10.1212/WNL.0000000000001816 PMID: 26163429; PubMed Central PMCID: PMC4603880.
59. Rasgon NL, Kenna HA, Wroolie TE, Kelley R, Silverman D, Brooks J, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer’s disease. Neurobiology of aging. 2011; 32(11):1942–8. https://doi.org/10.1016/j.neurobiolaging.2009.12.005 PMID: 20031276; PubMed Central PMCID: PMC2891925.
60. Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, Powers B, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology. 2011; 36(4):502–13. https://doi.org/10.1016/j.psyneuen.2010.08.002 PMID: 20810219; PubMed Central PMCID: PMC3021636.